The hottest infusion industry strategy seeks to up

The strategy of the infusion industry seeks to upgrade (Part 2)

the overall strategy of R & D, production and marketing changes

"every major change in the industry is painful, but after the pain is the real spring." Gu Weijun is very optimistic about the development of the domestic infusion industry. In order to support this prediction, he provided such a set of data: before the implementation of the large infusion industry in 1998, there were more than 390 infusion plants or workshops across the country, and the number increased to 407 after certification; In 1998, the total output of large-scale infusion was 192. The speed of electronic universal experimental machine was revised: 100 million bottles (bags), and in 2004, the national production and sales reached 4 billion bottles (bags); In 1998, plastic packaging infusion accounted for less than 5% of the total output of infusion in China. At the end of 2004, plastic bottles and soft bags accounted for 15% of the total output. GMP certification has brought the infusion industry to a new level as a whole. However, compared with developed countries, there is still a big gap in the industrial structure and product quality of our large infusion industry. For example, 80% of our large infusion products are ordinary infusion, and most of the high-end products come from foreign-funded enterprises; The proportion of plastic bottles and soft bags in China is about 15%, while 90% of infusion products in the United States are packaged in soft bags, and more than 70% of infusion products in Europe are plastic bottles and soft bags

experts believe that, like GMP certification, replacing butyl rubber plugs is also an opportunity to promote industrial upgrading. but "The replacement of butyl rubber stopper is not achieved overnight, but a systematic project. In addition to the most sensitive price factors, it also involves the production and quality management of butyl rubber stopper, the replacement of corking process and equipment in infusion plants, the matching of butyl rubber stopper and glass bottles, the stability and compatibility test of liquid medicine and rubber stopper, the use effect of disposable infusion set on infusion products packaged with butyl rubber stopper, etc., involving the R & D, production and marketing of infusion products Marketing and clinical application and other links. Different infusion products correspond to different butyl rubber plug formulas. This work will go through a long process. Replacing natural rubber plugs with butyl rubber plugs is a packaging modification problem. The reason why it causes such a big shock in the infusion industry is that this system engineering involves the problem of who pays for the progress of the industry. " Gu Weijun said

at present, insiders have noticed that leading enterprises such as Beijing Shuanghe Pharmaceutical Co., Ltd., Shanghai Huayuan Changfu Pharmaceutical Co., Ltd. and Shijiazhuang siyao Pharmaceutical Co., Ltd. have announced on different occasions that they will give up the glass bottle infusion Market and instead produce high-end infusion products such as plastic bottles and soft bags. Sichuan Kelun is also gradually reducing the share of glass bottle infusion. It is said that plastic bottles and soft bag infusion products will reach 30% of their output next year. Do these signs indicate that large infusion products are gradually upgrading

"developing plastic bottles and soft bags for infusion is a feasible solution for enterprises to eliminate natural rubber stoppers for infusion, and it is also the only way to realize the industrial upgrading of infusion industry. When the application of butyl rubber stoppers causes a series of problems, the residual concave deformation after the experiment should not be greater than: Grade a 3.00mm, realizing the transformation of plastic packaging from traditional plastic products to a" white pollution "is the development direction of enterprises, It is also a reflection of shortening the gap with developed countries. " However, Gu Weijun also pointed out that at present, there are three bottlenecks in the development of plastic packaging infusion in China that need to be broken through. The first is the technical bottleneck, which is manifested in China's weak product research and development capacity, the lack of medical polymer professionals, the need for investment in the upgrading of production processes, equipment and testing of infusion production enterprises, and the need for a substantial improvement in the operating level of workers; Second, infusion enterprises lack sufficient understanding, research and mastery of various policies and regulations related to infusion plastic packaging; Third, the market development of plastic packaging infusion requires time and energy, as well as sufficient investment

in terms of specific products, infusion products are internationally divided into five categories, namely, enteral and parenteral nutrient solutions; Renal products such as hemodialysis fluid and peritoneal dialysis fluid; Plasma substitutes; Therapeutic infusion and various flushing fluids. At present, domestic infusion production enterprises produce a large number of basic nutrient solutions in the first category of products, and fight a price war around low-end products, while other categories of products are rarely involved

in addition, the marketing mode of large infusion also needs to be innovated. "The sales of foreign infusion products promote one-stop service, while Chinese enterprises are still continuing the form of wholesaler agents, which is no different from the sales of ordinary goods. In order to return the price of infusion, we must treat it as a drug in marketing. Only when the infusion price of BAC automobile company, which produces mono supercar, is raised to a reasonable price, can plastic bottles and soft bags have a market." An insider said

according to Gu Weijun, multinational infusion production enterprises such as Baxter have their own marketing teams, which are specialized in educating nurses, and also help hospitals establish intravenous drug preparation centers to reduce medical disputes caused by improper dispensing. "Large infusion is like flowing blood. Its importance is unmatched by other drugs. Unfortunately, domestic enterprises do not understand this enough." Gu Weijun believes that the industrial upgrading of the infusion industry should not only be the upgrading of packaging, but also the upgrading of the overall industry development strategy, involving the R & D, production, marketing, distribution, clinical use and other links of infusion products. "Without such an upgrade, I'm afraid the progress of the industry will be slow."

source: China Medical News